BVT Bonus Zert GILD 27.06.2025/ DE000VD5T5D1 /
16/08/2024 17:05:28 | Chg.-0.130 | Bid19:43:28 | Ask19:43:28 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
67.850EUR | -0.19% | 67.920 Bid Size: 7,800 |
67.990 Ask Size: 7,800 |
Gilead Sciences Inc | - USD | 27/06/2025 | Call |
GlobeNewswire
01/07
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment o...
GlobeNewswire
01/07
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Offi...
GlobeNewswire
28/06
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
GlobeNewswire
26/06
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
GlobeNewswire
26/06
Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
GlobeNewswire
18/06
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...
GlobeNewswire
10/06
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...
GlobeNewswire
22/05
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...
GlobeNewswire
14/05
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
GlobeNewswire
09/05
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...
GlobeNewswire
09/05
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
08/05
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire
08/05
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
29/04
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire
19/04
ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies...
GlobeNewswire
10/04
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire
02/04
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
GlobeNewswire
01/04
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Fin...